STOCK TITAN

Curis Inc - CRIS STOCK NEWS

Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.

Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.

Core Business and Pipeline

Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.

Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.

Collaborations & Partnerships

Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.

Recent Achievements and Financial Condition

Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.

Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.

For more information, visit Curis's website at www.curis.com.

Rhea-AI Summary

Curis, a biotech firm, reported a net loss of $16.1 million for Q1 2022, compared to a loss of $9.9 million in Q1 2021. Revenues remained stable at $2.1 million. The company has a strong balance sheet with $120.7 million in cash, allowing operations to continue into 2024. Clinical updates include promising data for emavusertib, an IRAK4 inhibitor, though FDA has placed a partial hold on two studies. Initial safety data for CI-8993, an anti-VISTA antibody, were also discussed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
-
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. market close. A conference call is scheduled for the same day at 4:30 pm ET. The call can be accessed by dialing (888) 346-6389 in the U.S. or (412) 317-5252 internationally, and will also be available on Curis's website. Curis focuses on developing cancer therapeutics and has ongoing collaborations with Aurigene, ImmuNext, and Genentech.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
-
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced a partial clinical hold placed by the FDA on its TakeAim Lymphoma study for emavusertib. This follows an earlier hold on the TakeAim Leukemia study, affecting patient enrollment in both studies. Current participants can continue treatment at specified doses, pending reconsent. The FDA requests additional data on safety and efficacy related to emavusertib, including specific safety concerns. Curis aims to resolve this hold and is optimistic about the potential of emavusertib to address unmet needs in B-cell cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options for 380,850 shares to seven new employees, effective April 1, 2022. Each option has an exercise price equal to the April 1 closing price and a 10-year term, vesting over four years. This move aims to attract talent critical to Curis's innovative cancer therapeutics development. Curis is also involved in several collaborations, testing new cancer treatments, although the FDA has placed a partial hold on one of its trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focusing on cancer therapeutics, will have its CEO James Dentzer present at the 21st Annual Needham Virtual Healthcare Conference. This presentation will be available for on-demand viewing starting April 12, 2022, at 8:45 a.m. ET. Investors can access a live webcast on the company's website, with a replay available for 90 days post-event. Curis is known for its collaborations in immuno-oncology and its ongoing clinical trials for therapies like emavusertib, aimed at non-Hodgkin's lymphoma and acute myeloid leukemia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
conferences
-
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced a partial clinical hold by the FDA on its TakeAim Leukemia Phase 1/2a study due to safety concerns, particularly related to a patient fatality involving rhabdomyolysis, a known toxicity of emavusertib (CA-4948). While no new patients will be enrolled during this hold, current participants may continue treatment with lower doses. The FDA requires additional data on safety and efficacy before the study can resume. This hold does not affect the TakeAim Lymphoma study, but Curis has paused enrollment in that trial as well.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
none
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced the publication of a manuscript in Gastroenterology, detailing the role of IRAK4 in pancreatic ductal adenocarcinoma (PDAC) and the preclinical efficacy of the IRAK4 inhibitor emavusertib (CA-4948) combined with checkpoint immunotherapy. The study indicates that targeting IRAK4 could counteract tumor-induced T-cell exhaustion and improve responses to treatment. The research suggests potential broader applications of emavusertib in solid tumors, highlighting its promise in addressing significant unmet patient needs in cancer therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) reported its Q4 2021 financial results, showing a net loss of $13.6 million or $0.15 per share, compared to a net loss of $7.5 million in Q4 2020. Total revenues for 2021 were $10.6 million, slightly down from $10.8 million in 2020. Notably, Curis announced promising clinical progress in its pipeline, particularly for emavusertib (CA-4948) in leukemia treatment, and favorable safety data for CI-8993. The company plans to discuss a rapid FDA registration path and continues to see operational growth with new executive appointments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
-
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) will release its Q4 2021 financial results on February 24, 2022, after U.S. markets close. Management will host a conference call at 4:30 PM ET on the same day. Investors can join the call by dialing (888) 346-6389 (U.S.) or (412) 317-5252 (international). The call will also be available on Curis's website. The company specializes in cancer therapeutics, and its pipeline includes the IRAK4 kinase inhibitor CA-4948, currently in clinical trials for various hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will participate in two upcoming conferences: the B. Riley Virtual Oncology Conference on January 27, 2022, at 1:30 p.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be accessible on their website, and archived replays will be available for 90 days afterward.

Curis focuses on innovative cancer therapeutics, including trials on the IRAK4 inhibitor CA-4948.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
conferences

FAQ

What is the current stock price of Curis (CRIS)?

The current stock price of Curis (CRIS) is $3.08 as of December 20, 2024.

What is the market cap of Curis (CRIS)?

The market cap of Curis (CRIS) is approximately 25.8M.

What is Curis Inc.'s focus in the biotechnology sector?

Curis Inc. focuses on developing and commercializing innovative drug candidates for treating human cancers.

What are some of the key drug candidates in Curis's pipeline?

Curis's key drug candidates include Emavusertib (CA-4948), CUDC-907, CA-170, and CA-327, targeting various cancer pathways and conditions.

What significant collaborations does Curis have?

Curis has significant collaborations with Aurigene and Genentech, enhancing its capabilities in immuno-oncology and precision oncology.

What is the current status of Emavusertib's clinical trials?

Emavusertib is undergoing Phase 1/2 clinical trials for non-Hodgkin's lymphoma, acute myeloid leukemia, and myelodysplastic syndrome, and has received Orphan Drug Designation from the FDA.

How is Curis performing financially?

Curis reported a net loss of $47.4 million for the year ended December 31, 2023, but maintains a strong cash position with $56.3 million in cash, cash equivalents, and investments.

What recent achievements has Curis reported?

Curis has presented promising data from its clinical studies at major conferences like ASH and EHA, highlighting the progress of its drug candidates.

What is the significance of Curis's collaboration with Aurigene?

The collaboration with Aurigene provides Curis with exclusive licenses to several innovative molecules, bolstering its research in immuno-oncology and precision oncology.

What role does Genentech play in Curis's portfolio?

Genentech, under the Roche Group, is commercializing Erivedge®, a drug licensed from Curis, for treating advanced basal cell carcinoma.

What are Curis's future plans for its drug pipeline?

Curis plans to continue advancing its drug candidates through clinical trials, with a focus on achieving regulatory approvals and developing effective cancer treatments.

Where can I find more information about Curis Inc.?

For more information, visit Curis's website at www.curis.com.

Curis Inc

Nasdaq:CRIS

CRIS Rankings

CRIS Stock Data

25.82M
7.90M
6.78%
24.37%
2.28%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
LEXINGTON